Results 51 to 60 of about 210,319 (126)

Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis

open access: yesFrontiers in Neurology, 2018
Impulse control disorder (ICD), including pathological gambling, hypersexuality, and compulsive shopping has been linked to antiparkinsonian medication, especially dopamine agonists.
Pedro J. Garcia-Ruiz
doaj   +1 more source

Acromegaly: Beyond surgery

open access: yesIndian Journal of Endocrinology and Metabolism, 2013
Acromegaly is characterized by chronic, excess secretion of growth hormone (GH) from a pituitary adenoma, and elevated hepatic insulin-like growth factor 1 (IGF-1) levels.
Gaya Thanabalasingham, Ashley B Grossman
doaj   +1 more source

Aripiprazole, a Novel Option in the Management of Restless Legs Syndrome (RLS) Patients with Augmentation and/or Severe RLS Symptoms: A Report of 4 Cases

open access: yesNature and Science of Sleep, 2023
Elliott Kyung Lee,1,2 Naomi Spitale,2,3 Rebecca Robillard2 1Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada; 2Sleep Research Unit, Institute for Mental Health Research (IMHR), Ottawa, Ontario, Canada; 3Department of Medicine ...
Lee EK, Spitale N, Robillard R
doaj  

Adenosine AšŸA Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease

open access: yesParkinson's Disease, 2012
Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Current treatments for PD focus on dopaminergic therapies, including L-dopa and dopamine receptor agonists.
Carina J. Bleickardt   +3 more
doaj   +1 more source

Not all partial dopamine D2 receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse

open access: yes, 2010
Athan Spiros1, Robert Carr1, Hugo Geerts1,21In Silico Biosciences, Berwyn, PA, USA; 2School of Medicine, University of Pennsylvania, PA, USAAbstract: Species differences in physiology and unique active human metabolites contribute to the limited ...
Robert Carr, Hugo Geerts, Athan Spiros
core   +1 more source

Case Report: Near-fatal adverse effects of dopamine agonist for the treatment of restless legs syndrome

open access: yesFrontiers in Pharmacology
BackgroundThe dopaminergic system plays a central role in motor control, goal-directed behavior, and the pathophysiology of multiple diseases including restless legs syndrome.
Jeremiah B. Joyce   +2 more
doaj   +1 more source

Characterisation of AmphiAmR11, an amphioxus (Branchiostoma floridae) D2-dopamine-like G protein-coupled receptor.

open access: yesPLoS ONE, 2013
The evolution of the biogenic amine signalling system in vertebrates is unclear. However, insights can be obtained from studying the structures and signalling properties of biogenic amine receptors from the protochordate, amphioxus, which is an ...
Asha L Bayliss, Peter D Evans
doaj   +1 more source

Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease

open access: yes, 2003
Levodopa and the dopamine agonists are effective symptomatic treatments for Parkinson's disease, and all patients receive at least one of these agents during their illness. Long-term use of levodopa is commonly associated with motor complications such as
Jenner, P
core   +5 more sources

The History and Pharmacology of Dopamine Agonists [PDF]

open access: yesCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1984
ABSTRACTThe recognition of the dopaminergic properties of some ergot derivatives has initiated new therapeutical approaches in endocrinology as well as in neurology. The pharmacological characterization of the different ergot derivatives during the last decade has largely improved our understanding of central dopaminergic systems. Their development has
openaire   +2 more sources

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor

open access: yesNature Communications, 2018
Dopamine receptor agonists are used for the treatment of various psychiatric diseases. Here, the authors screen approximately three million compounds and identify a novel class of D1R agonists that do not have a catechol scaffold and possess promising ...
David L. Gray   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy